Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 501–600 of 1,003
Solanezumab and the amyloid hypothesis for Alzheimer’s disease
Le Couteur, D. G., Hunter, S., & Brayne, C. (2016) · BMJ · doi:10.1136/bmj.i6771 · Cited by 40
Alternative platelet activation pathways and their role in neurodegenerative diseases
Ferrer-Raventós, P., & Beyer, K. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105512 · Cited by 39
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
“However, less than one out of every eleven drug discovery programs makes it to market (Cummings et al., 2014).”
BackgroundZhou, Y., Xu, J., Hou, Y., Bekris, L., Leverenz, J. B., Pieper, A. A., Cummings, J., & Cheng, F. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12350 · Cited by 39
Self-citationTherapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 41
Yan, L., Li, H., Qian, Y., Zhang, J., Cong, S., Zhang, X., Wu, L., Wang, Y., Wang, M., & Yu, T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1334887 · Cited by 50
“The primary therapeutic approach to AD has been pharmacological, with only 10 FDA-approved treatments to date, including memantine, which is the newest treatment option despite having been available for a decade (Cummings et al., 2014).”
BackgroundThe vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Imindu Liyanage, S., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
Kozin, S. A., Barykin, E. P., Mitkevich, V. A., & Makarov, A. А. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090079 · Cited by 40
Designed Polymer Micelle for Clearing Amyloid Protein Aggregates via Up-Regulated Autophagy
Debnath, K., Jana, N. R., & Jana, N. R. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01196 · Cited by 39
Fronza, M. G., Baldinotti, R., Martins, M. C., Goldani, B. S., Dalberto, B. T., Kremer, F. S., Begnini, K. R., Pinto, L. D. S., Lenardao, E. J., Seixas, F. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43532-9 · Cited by 41
Abrogation of type-I interferon signalling alters the microglial response to Aβ1–42
Moore, Z., Mobilio, F., Walker, F. R., Taylor, J. M., & Crack, P. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-59917-0 · Cited by 45
Lalut, J., Payan, H., Davis, A., Lecoutey, C., Legay, R., Santos, J. S. O., Claeysen, S., Dallemagne, P., & Rochais, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59805-7 · Cited by 43
Zhou, J. H., Lv, Y., Mao, C., Duan, J., Gao, X., Wang, J., Yin, Z., Shi, W., Luo, J., Kang, Q., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.03.032 · Cited by 41
Li, L., Zou, Z., Liu, J., Xu, Z., Fu, Y., Tian, Y., & Zhang, W. (2021) · Chemical Science · doi:10.1039/d1sc00153a · Cited by 38
Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia
Albert, K., Niskanen, J., Kälvälä, S., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094334 · Cited by 47
Madrasi, K. J., Das, R., Abdul, H. M., Lin, L., Hyman, B. T., Lauffenburger, D. A., Albers, M. W., Rissman, R. A., Burke, J. M., Apgar, J. F., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12312 · Cited by 44
Leri, M., Bertolini, A., Stefani, M., & Bucciantini, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137225 · Cited by 43
“Furthermore, despite genetic and molecular evidence pointing to Aβ1–42 as a key player in AD pathogenesis [4], most trials with anti-amyloid therapies failed to provide evidence of treatment efficacy, suggesting that the anti-amyloid strategy should be abandoned [5] and new therapeutic avenues searched.”
BackgroundScuto, M. C., Modafferi, S., Rampulla, F., Zimbone, V., Tomasello, M., Spanò, S. M., Ontario, M. L., Palmeri, A., Salinaro, A. T., Siracusa, R., et al. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111686 · Cited by 43
Pandey, S., Jirásko, M., Lochman, J., Chvátal, A., Dvorakova, M. C., & Kučera, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091485 · Cited by 40
“This suggests that animal models are often poor predictors of human biology [32].”
BackgroundThrombin, a Key Driver of Pathological Inflammation in the Brain
Iannucci, J., & Grammas, P. (2023) · Cells · doi:10.3390/cells12091222 · Cited by 44
“Drugs that provide symptomatic benefits for the treatment of AD, such as cholinesterase inhibitors and the glutamate antagonist memantine, have been available for decades [137].”
BackgroundWhen Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum
Robillard, J. M., & Feng, T. L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161285 · Cited by 38
“These clinical trials, whether for pharmaceutical or technology-based interventions, are not possible without the participation of the dementia patient community [8].”
Hiremathad, A., Chand, K., & Keri, R. S. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13316 · Cited by 41
Honarpisheh, P., & McCullough, L. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14675 · Cited by 45
Quercetin Encapsulated Polymer Nanoparticle for Inhibiting Intracellular Polyglutamine Aggregation
Debnath, K., Jana, N. R., & Jana, N. R. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00518 · Cited by 40
Yang, X., Zhi, J., Leng, H., Chen, Y., Gao, H., Ma, J., Ji, J., & Hu, Q. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153571 · Cited by 40
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 42
“Additional information casting doubt on the amyloid hypothesis is the fact that, although several pre-clinical studies using transgenic mice overexpressing humanmutant APP /A (cid:2) havebeensuccessful,thefail-ure rate in AD clinical trials is approximately 99.6% [50, 51].”
InfluentialTeli, P., Kale, V. P., & Vaidya, A. (2023) · Cell and Tissue Research · doi:10.1007/s00441-023-03821-2 · Cited by 40
“…at the previously proposed “Rs” as the failure of several clinical trials in NDs has raised doubts about the translational ability of animal disease models to human patients (Table 1) (Anderson et al. 2017; Cummings et al. 2014; Olanow et al. 2008; Pfeuffer et al. 2016; Schneider et al. 2014).”
Open Access Could Transform Drug Discovery: A Case Study of JQ1
Arshad, Z., Smith, J. A., Roberts, M., Lee, W. H., Davies, B. M., Bure, K., Holländer, G. A., Dopson, S., Bountra, C., & Brindley, D. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1144587 · Cited by 48
“2012 [34], there is a dire need to come up with a solution to this age-related disorder in the context of”
BackgroundHebda, M., Bajda, M., Więckowska, A., Szałaj, N., Pasieka, A., Panek, D., Godyń, J., Wichur, T., Knez, D., Gobec, S., et al. (2016) · Molecules · doi:10.3390/molecules21040410 · Cited by 38
“Also, an alarmingly low number of drug candidates are undergoing clinical trials, with only a dozen compounds in Phase III [3,4].”
BackgroundWalsh, C., Drinkenburg, W. H. I. M., & Ahnaou, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.020 · Cited by 39
Li, X., Wang, H., Xu, Y., Liu, W., Gong, Q., Wang, W., Qiu, X., Zhu, J., Mao, F., Zhang, H., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00259 · Cited by 39
“(4) Changing the quinoline moiety of tacrine unit to 1,8-naphthyridine”
BackgroundLiao, Z., Su, H., Tan, Y., Qiu, Y., Zhu, J., Chen, Y., Lin, S., Wu, M., Mao, Y., Hu, J., et al. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4088 · Cited by 50
Da’adoosh, B., Marcus, D., Rayan, A., King, F., Che, J., & Goldblum, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-38508-8 · Cited by 42
The potential of memory enhancement through modulation of perineuronal nets
Duncan, J. A., Foster, R., & Kwok, J. C. F. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14672 · Cited by 38
Li, X., Lu, J., Xu, Y., Wang, J., Qiu, X., Fan, L., Li, B., Liu, W., Mao, F., Zhu, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.006 · Cited by 40
Human Amylin: From Pathology to Physiology and Pharmacology
Ling, W., Huang, Y., Qiao, Y.-C., Zhang, X., & Zhao, H. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190328111833 · Cited by 38
Age‐related neurodegenerative diseases
Duggan, M. R., Torkzaban, B., Ahooyi, T. M., Khalili, K., & Gordon, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29248 · Cited by 43
Use of Mendelian Randomization to Examine Causal Inference in Osteoporosis
Zheng, J., Frysz, M., Kemp, J. P., Evans, D. M., Smith, G. D., & Tobias, J. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00807 · Cited by 40
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 46
Singh, C. S. B., Choi, K. B., Munro, L., Wang, H. Y., Pfeifer, C. G., & Jefferies, W. A. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103503 · Cited by 36
“Furthermore, currently approved treatments for AD are considered “symptomatic” agents that seek to improve cognitive and behavioural symptoms but do not alter the underlying course of AD [2,5].”
BackgroundA geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials
Gonzales, M. M., Krishnamurthy, S., Garbarino, V. R., Daeihagh, A. S., Gillispie, G. J., Deep, G., Craft, S., & Orr, M. E. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111589 · Cited by 38
Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation
Kumar, D., Ashraf, G. M., Bilgrami, A. L., & Hassan, M. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.06.005 · Cited by 42
Alzheimer's Disease—Current Status and Future Directions
Bhardwaj, D., Mitra, C., Narasimhulu, C. A., Riad, A., Doomra, M., & Parthasarathy, S. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2017.0093 · Cited by 39
“To date, just five drugs, including four cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine, and memantine) and an N-methyl-d-aspartate receptor antagonist, are approved for AD treatment, with no real disease-modifying drugs available in the market.(67) Hence, novel strategies targeting Ab are un…”
Hiremathad, A., Chand, K., Esteves, A. R., Cardoso, S. M., Ramsay, R. R., Chaves, S., Keri, R. S., & Santos, M. A. (2016) · RSC Advances · doi:10.1039/c6ra03455a · Cited by 36
Early Stage Glycosylation Biomarkers in Alzheimer’s Disease
Regan, P., McClean, P. L., Smyth, T. J., & Doherty, M. (2019) · Medicines · doi:10.3390/medicines6030092 · Cited by 40
“However, the success of interventions in clinical trials has been very poor to date [28,29].”
BackgroundPREDICT: a checklist for preventing preanalytical diagnostic errors in clinical trials
Lippi, G., Meyer, A., Cadamuro, J., & Šimundić, A.-M. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1089 · Cited by 50
“6% in this specific clinical setting [19].”
Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease
Feustel, A. C., MacPherson, A., Fergusson, D. A., Kieburtz, K. D., & Kimmelman, J. (2019) · Neurology · doi:10.1212/wnl.0000000000008699 · Cited by 40
Advances in protein misfolding, amyloidosis and its correlation with human diseases
Kundu, D., Prerna, K., Chaurasia, R., Bharty, M. K., & Dubey, V. K. (2020) · 3 Biotech · doi:10.1007/s13205-020-2166-x · Cited by 42
Hippocampal alterations in glutamatergic signaling during amyloid progression in AβPP/PS1 mice
Hascup, K. N., Findley, C. A., Sime, L. N., & Hascup, E. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-71587-6 · Cited by 39
Defective Autophagy and Mitophagy in Alzheimer’s Disease: Mechanisms and Translational Implications
Chen, J., He, H., Ye, Q., Feng, F., Wang, W., Gu, Y., Han, R., & Xie, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02487-7 · Cited by 37
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 40
“Despite the growing number of AD patients, currently, only four drugs and one combined treatment are approved by the FDA and authorized by the European Union [45], which are donepezil, galantamine, and rivastigmine, three acetylcholinesterase (AChE) inhibitors, and memantine, an N-methyl-D-aspartate receptor antagonis…”
BackgroundSystematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol
Yaffe, K. S., Barnes, D. E., Rosenberg, D. E., Dublin, S., Kaup, A. R., Ludman, E. J., Vittinghoff, E., Peltz, C. B., Renz, A. D., Adams, K. J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180634 · Cited by 44
Re-thinking Alzheimer's disease therapeutic targets using gene-based tests
Kwok, M. K., Lin, S. L., & Schooling, C. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.001 · Cited by 35
“FDA since 2003, despite over 400 trials from 2002 to 2012 mainly targeting Aβ [12].”
BackgroundThe application of in vitro ‐derived human neurons in neurodegenerative disease modeling
D’Souza, G. X., Rose, S. E., Knupp, A., Nicholson, D. A., Keene, C. D., & Young, J. E. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24615 · Cited by 40
“Alzheimer's Research & Therapy, 6(4), 37. https://doi.org/10.1186/ alzrt269 Douvaras, P., & Fossati, V. (2015).”
BackgroundInfluentialAbdelwahab, G. M., Mira, A., Cheng, Y., Abdelaziz, T. A., Lahloub, M., & Khalil, A. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257071 · Cited by 40
Gao, X., Zhang, P., Chen, J., Zhang, L., Shang, N., Chen, J., Fan, R., Wang, Y., Huang, T., Niu, Q. L., et al. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00463-6 · Cited by 39
Gautam, V., Gaurav, A., Masand, N., Lee, V. S., & Patil, V. M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10489-3 · Cited by 44
“Therefore, the need of the hour is to have new treatments that can prevent or delay the onset of the disease, slowdown its progression, or improve patients’ symptoms more efficiently [208].”
BackgroundHadjichrysanthou, C., Ower, A. K., de Wolf, F., Anderson, R. M., & Initiative, F. T. A. D. N. (2018) · PLOS ONE · doi:10.1371/journal.pone.0190615 · Cited by 35
Sapkota, S., Huan, T., Tran, T., Zheng, J., Camicioli, R., Li, L., & Dixon, R. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00296 · Cited by 35
“Given the lack of success in developing therapeutics to reverse the course of neurodegeneration in aging after diagnosis (Cummings et al., 2014), research and clinical attention has shifted to multimodal risk detection in asymptomatic phases (Sperling et al.”
BackgroundMachine learning in Alzheimer’s disease drug discovery and target identification
Geng, C., Wang, Z., & Tang, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102172 · Cited by 34
Paolis, M. L. D., Paoletti, I., Zaccone, C., Capone, F., D’Amelio, M., & Krashia, P. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00423-y · Cited by 49
Asim, A., Jastrzębski, M. K., & Kaczor, A. A. (2025) · Molecules · doi:10.3390/molecules30142975 · Cited by 46
“…rhythmic brainwave fluctuations caused by the activation of local circuits of excitatory and fast-onset inhibitory neurons in the local field potential (LFP), resonating at 20–50 Hz and associated with numerous higher-order cognitive functions such as memory formation and attention selection [44].”
The role of DNA base excision repair in brain homeostasis and disease
Akbari, M., Morevati, M., Croteau, D., & Bohr, V. A. (2015) · DNA Repair · doi:10.1016/j.dnarep.2015.04.029 · Cited by 34
Kaur, A., Shuaib, S., Goyal, D., & Goyal, B. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04775a · Cited by 35
Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease
Fülöp, T., Munawara, U., Larbi, A., Desroches, M., Rodrigues, S., Catanzaro, M., Guidolin, A., Khalil, A., Bernier, F., Barron, A. E., et al. (2020) · CNS Drugs · doi:10.1007/s40263-020-00737-1 · Cited by 36
Klinedinst, B. S., Le, S. T., Larsen, B. A., Pappas, C. A., Hoth, N. J., Pollpeter, A., Wang, Q., Wang, Y., Yu, S., Wang, L., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201058 · Cited by 39
“therapeutic strategy to modulate AD [18], targeting specific aspects of one’s diet may be a potential preventative strategy to consider in the meantime.”
Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., & BUNGAU, S. G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03415-w · Cited by 35
Thermosensitive chitosan-based hydrogels supporting motor neuron-like NSC-34 cell differentiation
Stanzione, A., Polini, A., Pesa, V. L., Quattrini, A., Romano, A., Gigli, G., Moroni, L., & Gervaso, F. (2021) · Biomaterials Science · doi:10.1039/d1bm01129d · Cited by 38
Fernández‐Bolaños, J. G., & López, Ó. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2083956 · Cited by 41
“but just palliative treatments with moderate efficiency [3].”
BackgroundGáspár, A., Hutka, B., Ernyey, A. J., Tajti, B. T., Varga, B. T., Zádori, Z., & Gyertyán, I. (2022) · Scientific Reports · doi:10.1038/s41598-022-24292-5 · Cited by 40
He, Y., Xu, D., Yan, Z., Wu, Y., Zhang, Y., Tian, X., Zhu, J., Liu, Z., Cheng, W., Zheng, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043572 · Cited by 35
Isop, L. M., Neculau, A. E., Necula, R. D., Kakucs, C., Moga, M., & Dima, L. (2023) · Pharmaceuticals · doi:10.3390/ph16121714 · Cited by 41
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 42
Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review
Khzem, A. H. A., & Wali, S. M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s576701 · Cited by 46
“14,15 However, when drug repurposing is based on compounds that have successfully navigated the first phase of clinical trials, the attrition rates are substantially lower, at least with respect to safety concerns, during the subsequent clinical efficacy studies that target new indications.”
Iizuka, T., Morimoto, K., Sasaki, Y., Kameyama, M., Kurashima, A., Hayasaka, K., Ogata, H., & Goto, H. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000477343 · Cited by 35
Chand, K., Rajeshwari, K., Candeias, E., Cardoso, S. M., Chaves, S., & Santos, M. A. (2018) · Metallomics · doi:10.1039/c8mt00143j · Cited by 33
Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease
Ballard, C. G., Atri, A., Boneva, N., Cummings, J. L., Frölich, L., Molinuevo, J. L., Tariot, P. N., & Rakêt, L. L. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.04.001 · Cited by 38
“Developing new and more effective treatments for Alzheimer’s disease (AD) is an urgent priority; however, there have been no new licensed pharmacologic therapies for 15 years [1].”
BackgroundSelf-citationAmyloid-β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease
Kozin, S. A., Mitkevich, V. A., & Makarov, A. А. (2016) · Mendeleev Communications · doi:10.1016/j.mencom.2016.07.001 · Cited by 34
Kaur, A., Narang, S. S., Kaur, A., Mann, S., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00168 · Cited by 34
Wang, M., Cao, J., Amakye, W. K., Gong, C., Li, Q., & Ren, J. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.015 · Cited by 35
de Frutos‐Lucas, J., Frost, N. J., Erickson, K. I., Serrano, J. M., Maestú, F., Laws, S. M., & Brown, B. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101173 · Cited by 35
Kumar, S., Zomorrodi, R., Ghazala, Z., Goodman, M. S., Blumberger, D. M., Daskalakis, Z. J., Fischer, C. E., Mulsant, B. H., Pollock, B. G., & Rajji, T. K. (2020) · International Psychogeriatrics · doi:10.1017/s1041610220003518 · Cited by 39
“Search for novel treatments has not been successful to date with a failure rate of 99.6% for pharmacological trials (Cummings et al., 2014).”
BackgroundInfluentialHernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Rodgers, K. E., Wu, C., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12107 · Cited by 36
Green tea, epigallocatechin gallate and the prevention of Alzheimer’s disease: Clinical evidence
Lange, K. W., Lange, K. M., & Nakamura, Y. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.03.002 · Cited by 37
Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti, J., Corrigan, R. R., Servizi, S., & Casadesús, G. (2019) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2019/1.1212 · Cited by 33
“Though several studies clearly demonstrate that human amylin and Aβ have similar effects on LTP in the CNS and use of AMYR inhibitors ameliorates these deleterious effects36-39, other evidence suggests that Aβ (1-42) is incapable of signaling through the any of the AMYR to evoke any sort of cAMP response at a wide var…”
Li, K.-R., Wu, A., Tang, Y., He, X., Yu, C., Wu, J., Hu, G., & Yu, L. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02944-x · Cited by 38
“Thus, many patients receive little relief from treatment because of the delayed diagnosis of the disease [23].”
BackgroundAkter, S., Liu, Z., Simões, E. J., & Rao, P. R. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100169 · Cited by 49
“These FDA-approved medications are most effec-tive in the early to middle stages of the disease, offering symptomatic relief but not halting disease progression [ 17 , 20–23 ].”
Yang, W., Wen, H., Zhou, L.-X., Luo, Y., Hou, W., Wang, X., & Tian, X. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.02.002 · Cited by 33
Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease
Huang, Y., Shen, J. X., & Zhao, H. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15830 · Cited by 32
Foyet, H. S., Wado, E. K., Abaïssou, H. H. N., Assongalem, E. A., & Eyong, O. K. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/4568401 · Cited by 38
“However, the increased high failure rate of AD drug candidates during clinical trials highlights the complexity of this disease and therefore proves that the origin of memory dysfunction cannot be attributed to cholinergic damage alone [6].”
BackgroundMAM and C99, key players in the pathogenesis of Alzheimer’s disease
Pera, M., Montesinos, J., Larrea, D., Agrawal, R. R., VELASCO, K. R., Stavrovskaya, I. G., Yun, T. D., & Área-Gómez, E. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.016 · Cited by 37
Wang, Z., Heizhati, M., Wang, L., Li, M., Yang, Z., Lin, M., Abudereyimu, R., Hong, J., Yang, W., Yao, L., et al. (2022) · BMC Public Health · doi:10.1186/s12889-021-12417-w · Cited by 36
“Currently, there are no effective treatment options for the disease, leaving control of risk factors and prevention at pre-clinical stage as the effective way to delay disease onset [4].”
BackgroundDixon, R. A., & Lachman, M. E. (2019) · American Psychological Association eBooks · doi:10.1037/0000143-009 · Cited by 40
Experimentation and Approval Mechanisms
McClellan, A. (2022) · Econometrica · doi:10.3982/ecta17021 · Cited by 32
“The failure of numerous clinical trials for drugs to treat Alzheimer’s has discouraged investment in their development, as companies have become pessimistic about the chances of successful clinical trials (Cummings and Zhong (2015)).”
BackgroundNew Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics
Lutz, M. W., Crenshaw, D. G., Welsh-Bohmer, K. A., Burns, D. K., & Roses, A. D. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-016-0643-8 · Cited by 34
Targeting β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes
Liu, H., Yang, J., Wang, L., Xu, Y., Zhang, S., Lv, J., Ran, C., & Li, Y. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0185 · Cited by 33
Therapeutic peptides for CNS indications: Progress and challenges
Morimoto, B. H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.011 · Cited by 32
Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation
Matthes, D., Gapsys, V., Griesinger, C., & de Groot, B. L. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00325 · Cited by 33
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
